Global Sales of Counterfeit Drug Detection Devices Soar as Supply Chain Surveillance, and Anti-counterfeiting Solutions Firm up: New Study

January 2022

Estimated at a promising 5.9% CAGR between 2021 and 2026, global counterfeit drug detection devices market continues to benefit significantly from the rising awareness about sizeably large markets operating on adulterated pharmaceuticals packaging, and counterfeit medicines. A new Fairfield Market Research report suggests that an increasing number of anti-counterfeiting initiatives will drive sales of counterfeit drug detection devices. Several campaigns run by NGOs, healthcare professionals, and academic institutions, and globally successful initiatives such as Fight the Fakes are likely to bode well for expansion of market during the forecast period.

Key Highlights into Global Counterfeit Drug Detection Devices Market:

  • Global counterfeit drug detection devices market valuation to exceed US$1.3 Bn toward the end of 2026

  • Raman spectroscopes, and RFID analysers witness rapid sales growth

  • Portable/handheld devices to eye a higher CAGR than their benchtop counterparts

  • Drug testing laboratories remain dominant end users, pharma companies register fastest growth in demand

  • Packaging & labelling detection to remain the most sought-after application area

  • North America, with over a third of total market valuation, will retain its lead through 2026

Drug Testing Laboratories Record Significant Adoption of Counterfeit Drug Detection Devices

Drug testing landscape has been one of the faster-thriving markets over the recent past. While it has given a substantial push to adoption of counterfeit drug testing procedures, demand for drug testing services is especially climbing up to meet the objectives of the various investigational procedures. Toxicological laboratories have also registered notable demand growth in market. The report indicates drug testing laboratories as the top end user category in counterfeit drug detection devices market. Pharma companies on the other side prioritise regulatory compliance and are all set to register the fastest growth over the period of assessment. Demand is further likely to see a heavy upsurge owing to increasing stringency of surveillance across supply chains. The role of regulatory norms like the Drug Quality and Security Act, and the EU’s Falsified Medicines Directive (FMD) will remain instrumental in the establishment of effective anti-counterfeiting measures, thereby creating revenue generation opportunities for manufacturers of counterfeit drug detection devices.

End-to-end Anti-counterfeiting Solutions Underway

A greater number of companies in market have been considering investments in next-generation technologies to meet their long-term objective of developing their own end-to-end anti-counterfeiting solutions to gain a competitive edge. The likes of KGaA, and Clariant are at the forefront, and many will follow the suit. On the other hand, the trend of outsourcing is also picking up pace among drug manufacturers as they seek faster development with lesser sourcing complexity, and at upfront fixed costs. Limiting the access to sensitive patient data is what companies strive to achieve through outsourced track-and-trace systems.

Currently accounting for more than 34% share of the total market valuation, North America leads its way in global counterfeit drug detection devices market. The report forecasts North America’s dominance to remain intact in global counterfeit drug detection devices landscape through 2026.

The report has profiled some of the prominent participants in counterfeit drug detection devices space, including Thermo Fisher Scientific, Inc., B&W Tek., Olympus Corporation, PharmaSecure Inc., RIGAKU CORPORATION, Malvern Panalytical Ltd (Spectris Company), and Veripad.